(LLY) Eli Lilly - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US5324571083
Stock: Diabetes, Obesity, Cancer, Immunology, Neurology
Total Rating 71
Risk 79
Buy Signal 0.04
| Risk 5d forecast | |
|---|---|
| Volatility | 33.5% |
| Relative Tail Risk | -10.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.59 |
| Alpha | 5.36 |
| Character TTM | |
|---|---|
| Beta | 0.664 |
| Beta Downside | 0.955 |
| Drawdowns 3y | |
|---|---|
| Max DD | 34.48% |
| CAGR/Max DD | 1.35 |
EPS (Earnings per Share)
Revenue
Description: LLY Eli Lilly March 04, 2026
Eli Lilly and Company is a global pharmaceutical firm specializing in the discovery, development, manufacturing, and marketing of human pharmaceutical products.
The companys product portfolio is segmented across several therapeutic areas: cardiometabolic health (diabetes, obesity), oncology (various cancers), and immunology (autoimmune diseases, COVID-19). The pharmaceutical sector is characterized by lengthy and costly research and development cycles.
Key cardiometabolic products include Basaglar, Humalog, Mounjaro, and Zepbound. Oncology offerings feature Cyramza, Jaypirca, and Verzenio. Immunology products include Ebglyss, Olumiant, and Taltz. Eli Lilly also markets Emgality for migraines and Kisubla for Alzheimers disease.
Eli Lilly operates through a business model that includes both proprietary drug development and strategic collaborations. An example is the partnership with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family. Such collaborations are common in the pharmaceutical industry to share development costs and market reach.
For more detailed analysis of specific drug pipelines and market share, further research on ValueRay can be beneficial.
Headlines to watch out for
- Mounjaro, Zepbound sales drive diabetes, obesity revenue growth
- Oncology pipeline success impacts future earnings potential
- Immunology product launches expand market share
- Alzheimers disease drug development faces regulatory scrutiny
- Patent expirations threaten key product revenue streams
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 20.64b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 7.33 > 1.0 |
| NWC/Revenue: 31.30% < 20% (prev 9.69%; Δ 21.61% < -1%) |
| CFO/TA 0.15 > 3% & CFO 16.81b > Net Income 20.64b |
| Net Debt (35.34b) to EBITDA (27.94b): 1.27 < 3 |
| Current Ratio: 1.58 > 1.5 & < 3 |
| Outstanding Shares: last quarter (898.0m) vs 12m ago -0.57% < -2% |
| Gross Margin: 83.79% > 18% (prev 0.81%; Δ 8.30k% > 0.5%) |
| Asset Turnover: 68.18% > 50% (prev 57.22%; Δ 10.96% > 0%) |
| Interest Coverage Ratio: 33.16 > 6 (EBITDA TTM 27.94b / Interest Expense TTM 795.3m) |
Altman Z'' 4.02
| A: 0.18 (Total Current Assets 55.63b - Total Current Liabilities 35.23b) / Total Assets 112.48b |
| B: 0.22 (Retained Earnings 24.47b / Total Assets 112.48b) |
| C: 0.28 (EBIT TTM 26.37b / Avg Total Assets 95.60b) |
| D: 0.26 (Book Value of Equity 22.18b / Total Liabilities 85.94b) |
| Altman-Z'' Score: 4.02 = AA |
Beneish M -2.79
| DSRI: 1.05 (Receivables 20.16b/13.28b, Revenue 65.18b/45.04b) |
| GMI: 0.97 (GM 83.79% / 81.31%) |
| AQI: 0.78 (AQ_t 0.29 / AQ_t-1 0.37) |
| SGI: 1.45 (Revenue 65.18b / 45.04b) |
| TATA: 0.03 (NI 20.64b - CFO 16.81b) / TA 112.48b) |
| Beneish M-Score: -2.79 (Cap -4..+1) = A |
What is the price of LLY shares?
As of March 15, 2026, the stock is trading at USD 999.84 with a total of 1,446,678 shares traded.
Over the past week, the price has changed by -0.53%, over one month by -5.28%, over three months by -7.10% and over the past year by +23.79%.
Over the past week, the price has changed by -0.53%, over one month by -5.28%, over three months by -7.10% and over the past year by +23.79%.
Is LLY a buy, sell or hold?
Eli Lilly has received a consensus analysts rating of 4.24.
Therefore, it is recommended to buy LLY.
- StrongBuy: 16
- Buy: 7
- Hold: 4
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the LLY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 1214.3 | 21.5% |
| Analysts Target Price | 1214.3 | 21.5% |
LLY Fundamental Data Overview March 13, 2026
P/E Trailing = 43.6611
P/E Forward = 29.2398
P/S = 13.7295
P/B = 33.6988
P/EG = 1.0738
Revenue TTM = 65.18b USD
EBIT TTM = 26.37b USD
EBITDA TTM = 27.94b USD
Long Term Debt = 40.87b USD (from longTermDebt, last quarter)
Short Term Debt = 1.64b USD (from shortTermDebt, last quarter)
Debt = 42.50b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 35.34b USD (from netDebt column, last quarter)
Enterprise Value = 930.11b USD (894.88b + Debt 42.50b - CCE 7.27b)
Interest Coverage Ratio = 33.16 (Ebit TTM 26.37b / Interest Expense TTM 795.3m)
EV/FCF = 103.7x (Enterprise Value 930.11b / FCF TTM 8.97b)
FCF Yield = 0.96% (FCF TTM 8.97b / Enterprise Value 930.11b)
FCF Margin = 13.77% (FCF TTM 8.97b / Revenue TTM 65.18b)
Net Margin = 31.66% (Net Income TTM 20.64b / Revenue TTM 65.18b)
Gross Margin = 83.79% ((Revenue TTM 65.18b - Cost of Revenue TTM 10.56b) / Revenue TTM)
Gross Margin QoQ = 85.05% (prev 82.91%)
Tobins Q-Ratio = 8.27 (Enterprise Value 930.11b / Total Assets 112.48b)
Interest Expense / Debt = 0.29% (Interest Expense 123.0m / Debt 42.50b)
Taxrate = 19.71% (1.63b / 8.27b)
NOPAT = 21.17b (EBIT 26.37b * (1 - 19.71%))
Current Ratio = 1.58 (Total Current Assets 55.63b / Total Current Liabilities 35.23b)
Debt / Equity = 1.60 (Debt 42.50b / totalStockholderEquity, last quarter 26.54b)
Debt / EBITDA = 1.27 (Net Debt 35.34b / EBITDA 27.94b)
Debt / FCF = 3.94 (Net Debt 35.34b / FCF TTM 8.97b)
Total Stockholder Equity = 21.09b (last 4 quarters mean from totalStockholderEquity)
RoA = 21.59% (Net Income 20.64b / Total Assets 112.48b)
RoE = 97.85% (Net Income TTM 20.64b / Total Stockholder Equity 21.09b)
RoCE = 42.56% (EBIT 26.37b / Capital Employed (Equity 21.09b + L.T.Debt 40.87b))
RoIC = 34.18% (NOPAT 21.17b / Invested Capital 61.95b)
WACC = 7.99% (E(894.88b)/V(937.38b) * Re(8.36%) + D(42.50b)/V(937.38b) * Rd(0.29%) * (1-Tc(0.20)))
Discount Rate = 8.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.33%
[DCF] Terminal Value 70.26% ; FCFF base≈5.59b ; Y1≈3.67b ; Y5≈1.67b
[DCF] Fair Price = N/A (negative equity: EV 32.77b - Net Debt 35.34b = -2.57b; debt exceeds intrinsic value)
EPS Correlation: 48.57 | EPS CAGR: 30.61% | SUE: 0.70 | # QB: 0
Revenue Correlation: 95.54 | Revenue CAGR: 27.27% | SUE: 1.69 | # QB: 3
EPS next Quarter (2026-06-30): EPS=8.14 | Chg7d=+0.042 | Chg30d=+0.063 | Revisions Net=+2 | Analysts=19
EPS current Year (2026-12-31): EPS=34.66 | Chg7d=+0.000 | Chg30d=+0.491 | Revisions Net=+11 | Growth EPS=+43.2% | Growth Revenue=+26.0%
EPS next Year (2027-12-31): EPS=41.96 | Chg7d=+0.000 | Chg30d=+0.338 | Revisions Net=+7 | Growth EPS=+21.1% | Growth Revenue=+15.5%
[Analyst] Revisions Ratio: +0.20 (6 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.1% (Discount Rate 8.4% - Earnings Yield 2.3%)
[Growth] Growth Spread = +19.6% (Analyst 25.7% - Implied 6.1%)
P/E Forward = 29.2398
P/S = 13.7295
P/B = 33.6988
P/EG = 1.0738
Revenue TTM = 65.18b USD
EBIT TTM = 26.37b USD
EBITDA TTM = 27.94b USD
Long Term Debt = 40.87b USD (from longTermDebt, last quarter)
Short Term Debt = 1.64b USD (from shortTermDebt, last quarter)
Debt = 42.50b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 35.34b USD (from netDebt column, last quarter)
Enterprise Value = 930.11b USD (894.88b + Debt 42.50b - CCE 7.27b)
Interest Coverage Ratio = 33.16 (Ebit TTM 26.37b / Interest Expense TTM 795.3m)
EV/FCF = 103.7x (Enterprise Value 930.11b / FCF TTM 8.97b)
FCF Yield = 0.96% (FCF TTM 8.97b / Enterprise Value 930.11b)
FCF Margin = 13.77% (FCF TTM 8.97b / Revenue TTM 65.18b)
Net Margin = 31.66% (Net Income TTM 20.64b / Revenue TTM 65.18b)
Gross Margin = 83.79% ((Revenue TTM 65.18b - Cost of Revenue TTM 10.56b) / Revenue TTM)
Gross Margin QoQ = 85.05% (prev 82.91%)
Tobins Q-Ratio = 8.27 (Enterprise Value 930.11b / Total Assets 112.48b)
Interest Expense / Debt = 0.29% (Interest Expense 123.0m / Debt 42.50b)
Taxrate = 19.71% (1.63b / 8.27b)
NOPAT = 21.17b (EBIT 26.37b * (1 - 19.71%))
Current Ratio = 1.58 (Total Current Assets 55.63b / Total Current Liabilities 35.23b)
Debt / Equity = 1.60 (Debt 42.50b / totalStockholderEquity, last quarter 26.54b)
Debt / EBITDA = 1.27 (Net Debt 35.34b / EBITDA 27.94b)
Debt / FCF = 3.94 (Net Debt 35.34b / FCF TTM 8.97b)
Total Stockholder Equity = 21.09b (last 4 quarters mean from totalStockholderEquity)
RoA = 21.59% (Net Income 20.64b / Total Assets 112.48b)
RoE = 97.85% (Net Income TTM 20.64b / Total Stockholder Equity 21.09b)
RoCE = 42.56% (EBIT 26.37b / Capital Employed (Equity 21.09b + L.T.Debt 40.87b))
RoIC = 34.18% (NOPAT 21.17b / Invested Capital 61.95b)
WACC = 7.99% (E(894.88b)/V(937.38b) * Re(8.36%) + D(42.50b)/V(937.38b) * Rd(0.29%) * (1-Tc(0.20)))
Discount Rate = 8.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.33%
[DCF] Terminal Value 70.26% ; FCFF base≈5.59b ; Y1≈3.67b ; Y5≈1.67b
[DCF] Fair Price = N/A (negative equity: EV 32.77b - Net Debt 35.34b = -2.57b; debt exceeds intrinsic value)
EPS Correlation: 48.57 | EPS CAGR: 30.61% | SUE: 0.70 | # QB: 0
Revenue Correlation: 95.54 | Revenue CAGR: 27.27% | SUE: 1.69 | # QB: 3
EPS next Quarter (2026-06-30): EPS=8.14 | Chg7d=+0.042 | Chg30d=+0.063 | Revisions Net=+2 | Analysts=19
EPS current Year (2026-12-31): EPS=34.66 | Chg7d=+0.000 | Chg30d=+0.491 | Revisions Net=+11 | Growth EPS=+43.2% | Growth Revenue=+26.0%
EPS next Year (2027-12-31): EPS=41.96 | Chg7d=+0.000 | Chg30d=+0.338 | Revisions Net=+7 | Growth EPS=+21.1% | Growth Revenue=+15.5%
[Analyst] Revisions Ratio: +0.20 (6 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.1% (Discount Rate 8.4% - Earnings Yield 2.3%)
[Growth] Growth Spread = +19.6% (Analyst 25.7% - Implied 6.1%)